Oncology
PTEN Hamartoma Tumor Syndrome
2
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
PTEN hamartoma tumor syndrome is an early-stage landscape with 2 programs across 1 company. The most active players are Novartis. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved1
Analysis
Trial Status
1
clinical trials
Completed1 · 100%
Clinical Trials
Trial Activity
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
Completed·—·Phase 1/2·NCT02991807·46 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)